Scheffer IE et al (2017) ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. Epilepsia 58(4):512–521. https://doi.org/10.1111/epi.13709

Marini C et al (2004) Genetic architecture of idiopathic generalized epilepsy: clinical genetic analysis of 55 multiplex families. Epilepsia 45(5):467– 78. https://doi.org/10.1111/j.0013-9580.2004.46803.x

Loiseau J, Loiseau P, Guyot M, Duche B, Dartigues JF, Aublet B (1990) Survey of seizure disorders in the French southwest. I. Incidence of epileptic syndromes. Epilepsia 31(4):391-6. https://doi.org/10.1111/j.1528-1157.1990.tb05493.x

Hirsch E et al (2022) ILAE definition of the Idiopathic Generalized Epilepsy Syndromes: Position statement by the ILAE Task Force on Nosology and Definitions. Epilepsia 63(6):1475–1499. https://doi.org/10.1111/epi.17236

Jallon P, Latour P (2005) Epidemiology of idiopathic generalized epilepsies. Epilepsia 46(Suppl 9):10–14. https://doi.org/10.1111/j.1528-1167.2005.00309.x

Article  PubMed  Google Scholar 

Mohanraj R, Brodie MJ (2007) Outcomes of newly diagnosed idiopathic generalized epilepsy syndromes in a non-pediatric setting. Acta Neurol Scand 115(3):204–208. https://doi.org/10.1111/j.1600-0404.2006.00791.x

Jiang T, Zhang X, Zhang M, Liu M, Zhu H, Sun Y (2023) Drug-resistant idiopathic generalized epilepsy: A meta-analysis of prevalence and risk factors. Epilepsy Behav 146:109364. https://doi.org/10.1016/j.yebeh.2023.109364

Gomez-Ibanez A, McLachlan RS, Mirsattari SM, Diosy DC, Burneo JG (Feb 2017) Prognostic factors in patients with refractory idiopathic generalized epilepsy. Epilepsy Res 130:69–73. https://doi.org/10.1016/j.eplepsyres.2017.01.011

Cacao G, Parra J, Mannan S, Sisodiya SM, Sander JW (May 2018) Juvenile myoclonic epilepsy refractory to treatment in a tertiary referral center. Epilepsy Behav 82:81–86. https://doi.org/10.1016/j.yebeh.2018.03.002

Carter EG, Armour EA, Pagano LM, Reddy SB (2022) Epilepsy with myoclonic absences: a case series highlighting clinical heterogeneity and surgical management. Epileptic Disord 24(3):541–547. https://doi.org/10.1684/epd.2022.1420

Videira G, Raimundo R, Chorao R (2023) Epilepsy with myoclonic absences: A case series. Seizure 106:162–163. https://doi.org/10.1016/j.seizure.2023.02.017

Genton P, Bureau M (2006) Epilepsy with myoclonic absences. CNS Drugs 20(11):911–916. https://doi.org/10.2165/00023210-200620110-00004

Article  PubMed  Google Scholar 

Leppik IE (1995) Felbamate. Epilepsia 36 Suppl 2:S66–72. https://doi.org/10.1111/j.1528-1157.1995.tb06000.x

Article  CAS  PubMed  Google Scholar 

Leroy CT (1991) RF, Pilot study of FBM in adult medically refractory primary generalized seizure patients. Epilepsia 32:13

Sachdeo R (1992) Felbamate in juvenile myoclonic epilepsy. Epilepsia 33(3):118

French J, Smith M, Faught E, Brown L (1999) Practice advisory: The use of felbamate in the treatment of patients with intractable epilepsy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 52(8):1540-5. https://doi.org/10.1212/wnl.52.8.1540

Shah YD, Singh K, Friedman D, Devinsky O, Kothare SV (2016) Evaluating the safety and efficacy of felbamate in the context of a black box warning: A single center experience. Epilepsy Behav 56:50– 3. https://doi.org/10.1016/j.yebeh.2016.01.006

Cilio MR, Kartashov AI, Vigevano F (Nov 2001) The long-term use of felbamate in children with severe refractory epilepsy. Epilepsy Res 47:1–2. https://doi.org/10.1016/s0920-1211(01)00290-x

Reed L et al (Mar 2024) Efficacy of felbamate in a cohort of patients with epilepsy with myoclonic atonic seizures (EMAtS). Epilepsy Res 201:107314. https://doi.org/10.1016/j.eplepsyres.2024.107314

Rabinowicz S et al (2022) Felbamate for pediatric epilepsy-should we keep on using it as the last resort? Front Neurol 13:979725. https://doi.org/10.3389/fneur.2022.979725

Article  PubMed  PubMed Central  Google Scholar 

Page MJ et al (2021) PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ 372:n160. https://doi.org/10.1136/bmj.n160

Deeks JJ et al (2003) Evaluating non-randomised intervention studies. Health Technol Assess 7(27):iii-x, 1-173. https://doi.org/10.3310/hta7270

Guyatt G et al (2011) GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 64(4):383– 94. https://doi.org/10.1016/j.jclinepi.2010.04.026

Zupanc ML et al (2010) Efficacy of felbamate in the treatment of intractable pediatric epilepsy. Pediatr Neurol 42(6):396–403. https://doi.org/10.1016/j.pediatrneurol.2010.02.013

Heyman E, Levin N, Lahat E, Epstein O, Gandelman-Marton R (2014) Efficacy and safety of felbamate in children with refractory epilepsy. Eur J Paediatr Neurol 18(6):658– 62. https://doi.org/10.1016/j.ejpn.2014.05.005

Grosso S et al (Sep 2008) Efficacy and safety of felbamate in children under 4 years of age: a retrospective chart review. Eur J Neurol 15(9):940–946. https://doi.org/10.1111/j.1468-1331.2008.02215.x

Avanzini G, Canger R, Dalla Bernardina B, Vigevano F (1996) Felbamate in therapy-resistant epilepsy: an Italian experience. Felbamate Italian Study Group. Epilepsy Res 25(3):249– 55. https://doi.org/10.1016/s0920-1211(96)00070-8

Devinsky O, Kothari M, Savino L, Luciano D (1994) Felbamate for refractory absence seizures. J Epilepsy 7(3):189–194

Article  Google Scholar 

Kearney H, Delanty N (2009) Felbamate in an Adult Population with Severe Refractory Epilepsy. Ir Med J 102(10):326

CAS  PubMed  Google Scholar 

Rho JM, Donevan SD, Rogawski MA (1994) Mechanism of action of the anticonvulsant felbamate: opposing effects on N-methyl-D-aspartate and gamma-aminobutyric acidA receptors. Ann Neurol 35(2):229– 34. https://doi.org/10.1002/ana.410350216

Taglialatela M, Ongini E, Brown AM, Di Renzo G, Annunziato L (1996) Felbamate inhibits cloned voltage-dependent Na + channels from human and rat brain. Eur J Pharmacol 316(2–3):373–377. [Online]. Available: https://www.sciencedirect.com/science/article/abs/pii/S0014299996008023?via%3Dihub

Stefani A, Calabresi P, Pisani A, Mercuri NB, Siniscalchi A, Bernardi G (1996) Felbamate inhibits dihydropyridine-sensitive calcium channels in central neurons. J Pharmacol Exp Ther 277(1):121–127. [Online]. Available: https://jpet.aspetjournals.org/content/277/1/121.long

Perhach WI, Newton JL, Sofia JJ, Romanyshyn RD, Arndt WM Jr. (1986) Felbamate. In: Meldrum PR BS (ed) New anticonvulsant drugs. John Libbey, London/Paris, pp 117–123

Google Scholar 

Ticku MK, Kamatchi GL, Sofia RD (1991) Effect of anticonvulsant felbamate on GABAA receptor system. Epilepsia 32(3):389– 91. https://doi.org/10.1111/j.1528-1157.1991.tb04667.x

Sankar R, Holmes GL (Aug 2004) Mechanisms of action for the commonly used antiepileptic drugs: relevance to antiepileptic drug-associated neurobehavioral adverse effects. J Child Neurol 19(1):S6–14. https://doi.org/10.1177/088307380401900102

Ketter TA et al (1996) Felbamate monotherapy has stimulant-like effects in patients with epilepsy. Epilepsy Res 23(2):129– 37. https://doi.org/10.1016/0920-1211(95)00089-5

Liu L et al (Nov 2006) The mechanism of carbamazepine aggravation of absence seizures. J Pharmacol Exp Ther 319(2):790–798. https://doi.org/10.1124/jpet.106.104968

Cocito L, Primavera A (1998) Vigabatrin aggravates absences and absence status. Neurology 51(5):1519-20. https://doi.org/10.1212/wnl.51.5.1519

Wallace SJ (1998) Myoclonus and epilepsy in childhood: a review of treatment with valproate, ethosuximide, lamotrigine and zonisamide. Epilepsy Res 29(2):147– 54. https://doi.org/10.1016/s0920-1211(97)00080-6

Birnbaum D, Koubeissi M (2017) Unmasking of myoclonus by lacosamide in generalized epilepsy. Epilepsy Behav Case Rep 7:28–30. https://doi.org/10.1016/j.ebcr.2016.09.006

Article  PubMed  Google Scholar 

Healy DG, Ingle GT, Brown P (2009) Pregabalin- and gabapentin-associated myoclonus in a patient with chronic renal failure. Mov Disord 24(13):2028-9. https://doi.org/10.1002/mds.22286

Chaudrey KH et al (2012) Thinking beyond the obvious: hepatotoxicity secondary to idiosyncratic depakote toxicity. Am J Ther 19(6):403–406

Article  PubMed  Google Scholar 

Bromfield E, Dworetzky B, Wyszynski D, Smith C, Baldwin E, Holmes L (2008) Valproate teratogenicity and epilepsy syndrome. Epilepsia 49(12):2122–2124

Pellock JM, Wilder B, Deaton R, Sommerville KW (2002) Acute pancreatitis coincident with valproate use: a critical review. Epilepsia 43(11):1421–1424

Steinhoff BJ et al (2021) Behavioral adverse events with brivaracetam, levetiracetam, perampanel, and topiramate: a systematic review. Epilepsy Behav 118:107939

Article  PubMed  Google Scholar